(Q33195131)

23 July 2017

title

Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone (English)

1 reference

23 July 2017

Improvement In Indices Of Health Status In Outpatients With Schizophrenia Switched To Ziprasidone (English)

1 reference

https://api.crossref.org/works/10.1097/01.JCP.0000095347.32154.08

3 April 2024

0 references

1

Peter J. Weiden

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14624190

3 April 2024

author name string

George Simpson

3

1 reference

23 July 2017

David G. Daniel

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14624190

3 April 2024

Steven J. Romano

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14624190

3 April 2024

language of work or name

English

0 references

publication date

1 December 2003

1 reference

full work available at URL

23 July 2017

https://journals.lww.com/10.1097/01.jcp.0000095347.32154.08

1 reference

https://api.crossref.org/works/10.1097/01.JCP.0000095347.32154.08

Journal of Clinical Psychopharmacology

3 April 2024

published in

1 reference

23 July 2017

volume

23

1 reference

23 July 2017

issue

6

1 reference

23 July 2017

page(s)

595-600

1 reference

Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group

23 July 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1097/01.JCP.0000095347.32154.08

Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial

3 April 2024

2

1 reference

https://api.crossref.org/works/10.1097/01.JCP.0000095347.32154.08

An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder

3 April 2024

3

1 reference

https://api.crossref.org/works/10.1097/01.JCP.0000095347.32154.08

Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia.

3 April 2024

6

1 reference

https://api.crossref.org/works/10.1097/01.JCP.0000095347.32154.08

The apparent effects of ziprasidone on plasma lipids and glucose.

3 April 2024

7

1 reference

https://api.crossref.org/works/10.1097/01.JCP.0000095347.32154.08

Neuroleptic-induced hyperprolactinemia

3 April 2024

8

1 reference

https://api.crossref.org/works/10.1097/01.JCP.0000095347.32154.08

3 April 2024

Identifiers

1 reference

23 July 2017

1 reference